Provider Briefing: Xelstrym Availability in 2026

Xelstrym (Dextroamphetamine transdermal system) is the first and only FDA-approved amphetamine patch for ADHD. Approved in March 2023 and commercially launched in 2024 by Noven Pharmaceuticals, it offers a novel transdermal delivery option for patients aged 6 and older. However, real-world access remains a significant challenge for patients.

This guide provides prescribers with a concise overview of Xelstrym's current availability landscape, cost considerations, alternative options, and tools to help patients access their medication.

Timeline: Xelstrym from Approval to Present

• March 2023: FDA approves Xelstrym (Dextroamphetamine transdermal system) for ADHD in adults and pediatric patients 6 years and older
• 2024: Commercial launch through Noven C.A.N. (Care Access Network) Partner Pharmacy distribution model
• 2024–2025: Gradual partner pharmacy enrollment; limited but growing availability
• 2026: Availability improving but still restricted primarily to enrolled C.A.N. partner pharmacies; not yet widely stocked at major chains

Xelstrym has not been formally listed on the FDA drug shortage database. The access challenges are structural — related to distribution model and pharmacy adoption — rather than manufacturing shortfalls.

Prescribing Implications

When prescribing Xelstrym, providers should be aware of several practical considerations:

Pharmacy Access

Patients cannot fill Xelstrym at just any pharmacy. Only pharmacies enrolled in Noven's C.A.N. Partner Pharmacy network can reliably dispense it. Before writing a prescription, consider:

• Verifying that the patient has access to a C.A.N. Partner Pharmacy (use the pharmacy finder at xelstrym.com or the Mindful Patch app)
• Advising patients to contact the Noven C.A.N. Patient Access Team at 833-483-2178 before their first fill
• Being prepared for potential prior authorization requirements from the patient's insurer

Insurance Coverage

Coverage for Xelstrym is inconsistent across payers:

• Many commercial plans require prior authorization
• Some plans mandate step therapy (documented trial of oral stimulants before approving the patch)
• Some plans do not cover Xelstrym at all
• Medicare Part D and Medicaid coverage varies by state and plan

Anticipate appeals and prior authorization submissions. Documenting clinical rationale for the transdermal route (e.g., dysphagia, GI absorption concerns, adherence challenges, need for mid-day dose flexibility) strengthens these requests.

Dosing and Administration

Xelstrym is available in four patch strengths: 4.5 mg/9 hr, 9 mg/9 hr, 13.5 mg/9 hr, and 18 mg/9 hr. Key prescribing points:

• Apply one patch daily to the hip; wear for up to 9 hours, then remove
• Rotate application sites
• Patients should avoid exposing the patch site to direct external heat sources
• The ability to remove the patch mid-day provides dose flexibility not available with oral extended-release formulations
• Application site reactions (pain, itching, erythema) are common — reported in 45–73% of patients during dose optimization. Most are mild to moderate and do not require discontinuation

Current Availability Picture

The primary availability constraint is the limited distribution footprint. Key factors:

• C.A.N. Partner Pharmacy model: Only enrolled pharmacies can stock and dispense Xelstrym
• No generic equivalent: Brand-only status limits pharmacy incentive to stock
• DEA Schedule II quotas: Manufacturing quotas for amphetamines constrain overall production capacity
• Low prescriber awareness: As a newer product, Xelstrym has lower market penetration than established stimulants

Noven continues to expand the C.A.N. network, and some partner pharmacies offer home delivery. Providers can direct patients to the pharmacy finder tools or to Medfinder for Providers for availability data.

Cost and Access Considerations

Cost is a meaningful barrier for many patients:

• Cash price: $350–$500/month (30-day supply)
• Copay Savings Program: Noven offers a manufacturer copay card that can reduce costs to $0 for eligible commercially insured patients
• Patient Assistance: The Noven C.A.N. Patient Access Team (833-483-2178) can help uninsured or underinsured patients explore options
• Comparison: Generic oral Dextroamphetamine costs $20–$40/month; generic Lisdexamfetamine costs $30–$80/month

For a patient-facing resource on savings, direct patients to our guide on saving money on Xelstrym.

Tools and Resources for Providers

Medfinder for Providers

Medfinder helps providers and their staff check medication availability across pharmacies. This is particularly useful for controlled substances like Xelstrym where stock varies significantly by location.

Noven C.A.N. Resources

• Partner Pharmacy Finder: Available at xelstrym.com and via the Mindful Patch app
• Patient Access Team: 833-483-2178 (Mon–Fri, 9 AM–7 PM EST)
• Copay Savings Enrollment: xelstrym.com or Mindful Patch app

Alternative Prescribing Options

When Xelstrym cannot be accessed, consider these alternatives:

• Generic Lisdexamfetamine (Vyvanse): Prodrug of Dextroamphetamine, widely available, $30–$80/month
• Generic Dextroamphetamine (oral IR/ER): Same active ingredient, $20–$40/month
• Generic Mixed Amphetamine Salts ER (Adderall XR): Widely stocked, $25–$60/month
• Methylphenidate-based options: For patients who may benefit from a different stimulant class

For a patient-facing comparison, see alternatives to Xelstrym.

Looking Ahead

Xelstrym's unique transdermal delivery offers genuine clinical advantages for select patients — particularly those with adherence challenges, swallowing difficulties, or who benefit from the ability to modulate treatment duration by removing the patch. As Noven's distribution network matures and prescriber familiarity grows, access is expected to improve.

In the meantime, providers play a critical role in:

• Setting realistic expectations about pharmacy access
• Connecting patients with Noven's access resources proactively
• Having alternative medication plans ready
• Documenting clinical rationale for prior authorization when needed

For ongoing availability monitoring, Medfinder for Providers offers a practical solution for tracking stimulant stock in your area.

Final Thoughts

Xelstrym is not in a formal drug shortage, but the practical reality for patients is that finding and affording it remains challenging. Providers who understand the distribution model, proactively connect patients with access resources, and maintain flexible prescribing plans will deliver the best outcomes for their ADHD patients in 2026.